A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non–Small Cell Lung Cancer

Tina Cascone, Boris Sepesi, Heather Y. Lin, Neda Kalhor, Edwin R. Parra, Mei Jiang, Myrna C.B. Godoy, Jianjun Zhang, Frank V. Fossella, Anne S. Tsao, Vincent K. Lam, Charles Lu, Frank E. Mott, George R. Simon, Mara B. Antonoff, Reza J. Mehran, David C. Rice, Carmen Behrens, Annikka Weissferdt, Cesar MoranAra A. Vaporciyan, J. Jack Lee, Stephen G. Swisher, Don L. Gibbons, Ignacio I. Wistuba, William N. William, John V. Heymach

Research output: Contribution to journal › Article › peer-review

21 Scopus citations

Fingerprint

Dive into the research topics of 'A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non–Small Cell Lung Cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences